^
Association details:
Biomarker:No biomarker
Cancer:Mediastinal B Cell Lymphoma
Drug:Keytruda (pembrolizumab) (PD1 inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody indicated:...for the treatment of adult and pediatric patients with refractory PMBCL, or who have relapsed after 2 or more prior lines of therapy....KEYTRUDA is not recommended for treatment of patients with PMBCL who require urgent cytoreductive therapy.